The collapse of these ketamine chains are a warning of challenges that threaten to puncture the psychedelics bubble.May 16, 2023Check out STAT+Sponsored By Molly Ferguson for STAT STAT+ | Ketamine clinics' bust serves as warning of business challenge facing psychedelic therapy The collapse of these ketamine chains are a warning of challenges that threaten to puncture the psychedelics bubble. By Isabella Cueto and Olivia Goldhill STAT+ | FTC files lawsuit to block Amgen's purchase of Horizon Therapeutics The acquisition, announced in December, was seen as another move by a large pharma company to build out its rare disease pipeline. By Andrew Joseph AstraZeneca is third member to leave PhRMA in five months AstraZeneca has decided to leave the brand drug lobbying powerhouse PhRMA halfway through the year, the organization said. By Rachel Cohrs John Locher/AP 'We're failing to make progress': Studies show ongoing toll of premature Black deaths The authors said they undertook the new analysis hoping to add urgency to efforts to end the crisis of premature Black deaths. By Usha Lee McFarling Pfizer RSV vaccine seen as effective against severe disease, FDA documents say The finding, in an FDA analysis, was released in advance of a Thursday meeting of a committee of outside advisers. By Helen Branswell STAT+ | AI leaders issue a plea to Congress: Regulate us, and quickly A Senate subcommittee called for aggressive regulation of generative AI tools — and the makers and users of the technologies agreed. By Casey Ross Adobe Opinion: A breakthrough drug will require big changes for eye care doctors The ultimate success of Syfovre, as well as the preservation of patients' vision, will depend on an effective referral loop. By Antonio Capone Jr. STAT+ | Biden drug czar to summon naloxone makers to White House to discuss pricing Narcan, the naloxone product that received over-the-counter approval to reverse opioid overdose, remains cost-prohibitive for many consumers. By Lev Facher More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments